Keywords
Adultos
Neumonía adquirida en la comunidad
respuesta inmune
Categories
How to Cite
Abstract
La neumonía adquirida en la comunidad (NAC) es una infección del parénquima pulmonar adquirida fuera de recintos hospitalarios, siendo la enfermedad infecciosa que causa mayor morbimortalidad a nivel global y una de las principales causas de muerte por infección respiratoria en Chile. Las citoquinas son proteínas secretadas durante la respuesta inmune frente a una infección para modular la respuesta de las células efectoras, con un rol fisiopatológico en la evolución y gravedad de ciertas enfermedades. Con el fin de conocer el rol de las distintas citoquinas, como TNF-, IL-5, IL-1, IL-8, IL-10 en la evolución de la NAC en el adulto, se revisó la literatura científica publicada en las bases de datos PubMed y Science Direct, entre los años 2020-2025, usando las palabras claves: citoquinas, adultos, neumonía adquirida en la comunidad y respuesta inmune.
References
Oliveira e Silva PG, Cerqueira Batista Filho LA, Pérez Flores I, Vilins e Silva V, Toledo Maciel A, Seraphim Medeiros L. Neumonía adquirida en la comunidad: epidemiología, diagnóstico, escalas pronósticas de gravedad y nuevas opciones terapéuticas. Medwave. 2023;23(11):e2719. http://doi.org/10.5867/medwave.2023.11.2719
Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, et al. Community-acquired pneumonia. Lancet. 2021;398(10303):802–12. doi:10.1016/S0140-6736(21)00630-9.
Brands X, Haak B, Klarenbeek A, Otto N, Faber D, Lutter R et al. Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia. Frontiers in Immunology. 2020;11: 2
Theilacker C, Sprenger R, Leverkus F, Walker J, Häckl D, von Eiff C, et al. Population-based incidence and mortality of community-acquired pneumonia in Germany. PLoS One. 2021;16(6):e0253118. doi:10.1371/journal.pone.0253118.
Poovieng J, Sakboonyarat B, Nasomsong W. Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital. Sci Rep. 2022;12:9004. doi:10.1038/s41598-022-12904-z.
Arancibia FH, Saldías PF, Pérez CC, Muñoz NK, Ruiz CM, Lasso BM, et al. Consenso Chileno de Neumonía Adquirida en la Comunidad en Adultos. Rev Chil Enferm Respir. 2023;39(1):11–107. Disponible en: https://www.scielo.cl/pdf/rcher/v39n1/0717-7348-rcher-39-01-0011.pdf
Hastak PS, Andersen CR, Kelleher AD, Sasson SC. Frontline workers: Mediators of mucosal immunity in community acquired pneumonia and COVID-19. Front Immunol. 2022;13:983550. doi:10.3389/fimmu.2022.983550
Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU. Pharmacol Ther. 2020 Aug 15;217:107663. doi:10.1016/j.pharmthera.2020.107663.
Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. The Lancet. 2021;398(10303):906–19.
Gadsby NJ, Musher DM. The microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to host transcriptional signatures. Clin Microbiol Rev. 2022 Dec;35(4):e00015-22. doi:10.1128/cmr.00015-22.
Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, et al. Pneumonia. Nat Rev Dis Primers. 2021;7(1):25. doi:10.1038/s41572-021-00259-0.
Dimitropoulos D, Karmpadakis M, Paraskevas T, Michailides C, Lagadinou M, Platanaki C, et al. Inflammatory biomarker-based clinical practice in patients with pneumonia: A systematic review of randomized controlled trials. Rom J Intern Med. 2024;62(3):241–259. doi:10.2478/rjim-2024-0013.
Kühnapfel A, Horn K, Klotz U, Kiehntopf M, Rosolowski M, Loeffler M, et al. Genetic regulation of cytokine response in patients with acute community-acquired pneumonia. Genes (Basel). 2022;13(1):111. doi:10.3390/genes13010111.
Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020 Dec 3;383(23):2255–73. doi:10.1056/NEJMra2026131.
Rosolowski M, Oberle V, Ahnert P, Creutz P, Witzenrath M, Kiehntopf M et al. Dynamics of cytokines, immune cell counts and disease severity in patients with community-acquired pneumonia – Unravelling potential causal relationships. Cytokine. 2020;136:155263.
Wautier JL, Wautier MP. Pro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans: A Mini Review. Int J Mol Sci. 2023 Jun 1;24(11):9647. doi:10.3390/ijms24119647
Jin W, Liao L, Qin T, Guan X, Gao H, et al. Recent advances in nanomedicine therapy for bacterial pneumonia. Chin Chem Lett. 2025 Feb;36:110920. doi:10.1016/j.cclet.2025.110920.
Marriott HM, Gascoyne KA, Gowda R, Geary I, Nicklin MJH, Iannelli F, et al. Interleukin-1β regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages. Infect Immun. 2012 Mar;80(3):1140–9. doi:10.1128/IAI.05697-11.
Zawawi ZM, Kalyanasundram J, Mohd Zain R, Thayan R, Basri DF, Yap WB. Prospective Roles of Tumor Necrosis Factor-Alpha (TNF-α) in COVID-19: Prognosis, Therapeutic and Management. Int J Mol Sci. 2023 Mar 24;24(7):6142. doi:10.3390/ijms24076142.
Chen R., Lan Z., Ye J., Pang L., Liu Y., Wu W., Qin X., Guo Y., Zhang P. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Front. Immunol. 2021;12:589095. doi: 10.3389/fimmu.2021.589095.
Udomsinprasert W., Jittikoon J., Sangroongruangsri S., Chaikledkaew U. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis. J. Clin. Immunol. 2020;41:11–22. doi: 10.1007/s10875-020-00899-z
Davidson M, Menon S, Chaimani A, Evrenoglou T, Ghosn L, Graña C, et al. Interleukin-1 blocking agents for treating COVID-19. Cochrane Database Syst Rev. 2022;1:CD015308. doi:10.1002/14651858.CD015308.
Chen, Y., Ye, X., Escames, G. et al. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell Mol Biol Lett 28, 51 (2023). https://doi.org/10.1186/s11658-023-00462-9
Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. Pediatrics. 2020;146(6):e202011452. doi:10.1542/peds.2020-011452.
Wang J, Nikrad MP, Phan QT, Wang Y, Gao L, Liu Y, et al. The Role of Interleukin-8 in Lung Inflammation and Injury: Implications for the Management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome. Front Pharmacol. 2021;12:808797. doi:10.3389/fphar.2021.808797.
Schmidt GA, Hall JB. Pulmonary mechanics during mechanical ventilation. J Crit Care. 2009;24(1):10–17. doi:10.1016/j.jcrc.2008.05.006.
Wiersinga WJ, van der Poll T. Immunopathophysiology of human sepsis. eBioMedicine. 2022 Dec 2;86:104363. doi:10.1016/j.ebiom.2022.104363.
Zhou Y, Wang Y, Zhang Y, Liu Y, Zhang X, Wang L, et al. Application Prospect of the SOFA Score and Related Modification Research in Sepsis. J Inflamm Res. 2023;16:1661–77. doi:10.2147/JIR.S403472.
Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, et al. Community-acquired pneumonia. Lancet. 2021;398(10303):802–12. doi:10.1016/S0140-6736(21)00630-9.
Xu Z, Wang XM, Cao P, Zhang C, Feng CM, Zheng L, et al. Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Int J Med Sci. 2022;19(1):74–81. doi:10.7150/ijms.67028
Dao BN, Le HDT, Nguyen KX, Tran VT. Relationship between serum TNF-α, IL-6, and IL-10 levels and disease severity, and changes in the cytokines after treatment in patients with bacterial community-acquired pneumonia. Pneumon. 2023;36(4):1–8. doi:10.18332/pne/170181.
Rosolowski M, Oberle V, Ahnert P, Creutz P, Witzenrath M, Kiehntopf M et al. Dynamics of cytokines, immune cell counts and disease severity in patients with community-acquired pneumonia – Unravelling potential causal relationships. Cytokine. 2020;136:155263.
Méndez, R., Aldás, I. and Menéndez, R.,. Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac). Journal of Clinical Medicine. 2020; 9(2): 7
Xu Z, Wang X-M, Cao P, Zhang C, Feng C-M, Zheng L, et al. Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Int J Med Sci. 2022;19(1):74–81. doi:10.7150/ijms.67028.
Abakar MAA, Hamad DH, Faisal E, et al. Comparative analysis of immunological biomarkers in COVID-19 and bacterial pneumonia. J Med Life. 2023;16(12):1844–1851. doi:10.25122/jml-2023-0273.
Méndez, R., Aldás, I. and Menéndez, R.,. Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac). Journal of Clinical Medicine. 2020; 9(2): 7
Rosolowski M, Oberle V, Ahnert P, Creutz P, Witzenrath M, Kiehntopf M et al. Dynamics of cytokines, immune cell counts and disease severity in patients with community-acquired pneumonia – Unravelling potential causal relationships. Cytokine. 2020;136:155263.
Sanz Codina M, Zeitlinger M. Biomarkers predicting tissue pharmacokinetics of antimicrobials in sepsis: A Review. Clinical Pharmacokinetics. 2022;61(5):593–617.
Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–29.
Ramasamy S, Subbian S. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clinical Microbiology Reviews. 2021 May 12;34(3).
Zanza C, Romenskaya T, Manetti AC, Franceschi F, La Russa R, Bertozzi G, et al. Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina. 2022 Jan 18;58(2):144.
Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, Tarhriz V, Farjami A, Ghasemian Sorbeni F, et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virology Journal. 2022 May 26;19(1).
Zanza C, Romenskaya T, Manetti AC, Franceschi F, La Russa R, Bertozzi G, et al. Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina. 2022 Jan 18;58(2):144.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2025 Valentina Vasconcello Ortiz, René Olave Gomez